On April 4, 2022, following European Medicines Agency (EMA) authorization, Verzenios® in combination with endocrine therapy, was approved for the adjuvant treatment of adult patients with early-stage breast cancer that is hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), lymph node-positive, and at high risk of recurrence (1). The gene discussed is HR; the disease is breast carcinoma.